Art. -Nr.: HY-N6607

Tryptanthrin

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

Tryptanthrin is an indole quinazoline that could be an alkaloid from indigo-bearing plants. Tryptanthrin is a potent and orally active cellular Leukotriene (LT) biosynthesis inhibitor. Tryptanthrin has anticancer activity. Tryptanthrin suppresses the expression levels of NOS1, COX-2, and NF-κB and regulates the expression levels of IL-2, IL-10, and TNF-α.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.83%
CAS. Nr.: 13220-57-0
Formel: C₁₅H₈N₂O₂
Molecular Weight:248.24

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Tryptanthrin Chemical Structure

CAS. Nr.: 13220-57-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

IL-2

nNOS

IL-6

IL-10

IL-12

Alle Leukotriene Receptor Isoform-spezifische Produkte anzeigen :

Alle NO Synthase Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle COX Isoform-spezifische Produkte anzeigen :

Alle TNF Receptor Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	9 μM Compound: 47	Anticancer activity against human A-431 cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay Anticancer activity against human A-431 cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay	[PMID: 36375335]
A498	GI₅₀	0.95 μM Compound: 1 (Tryptanthrine)	Tested for in vitro cytotoxic activity against renal A498 human cancer cell lines Tested for in vitro cytotoxic activity against renal A498 human cancer cell lines	[PMID: 12161121]
A498	GI₅₀	0.95 μM Compound: 1; Try	Growth inhibition of human A498 cells assessed as reduction in cell viability Growth inhibition of human A498 cells assessed as reduction in cell viability	[PMID: 38665827]
A498	GI₅₀	0.95 μM Compound: 47	Growth inhibition of human A498 cells by SRB method Growth inhibition of human A498 cells by SRB method	[PMID: 36375335]
A549	IC₅₀	>100 μM Compound: 1; Try	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability Antiproliferative activity against human A549 cells assessed as inhibition of cell viability	[PMID: 38665827]
A549	IC₅₀	>150 μM Compound: 1; Try	Antiproliferative activity against human A549 cells assessed as cell growth inhibition Antiproliferative activity against human A549 cells assessed as cell growth inhibition	[PMID: 38665827]
A549	IC₅₀	74.71 μM Compound: 1; Try	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 38665827]
A549	IC₅₀	74.71 μM Compound: 1; Try	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 38665827]
A549	IC₅₀	8.25 μM Compound: 1; Try	Antiproliferative activity against human A549 cells incubated by 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated by 48 hrs by MTT assay	[PMID: 38665827]
A549/CDDP	IC₅₀	>100 μM Compound: 1; Try	Antiproliferative activity against human A549/DDP cells assessed as inhibition of cell viability Antiproliferative activity against human A549/DDP cells assessed as inhibition of cell viability	[PMID: 38665827]
Bel-7402	IC₅₀	41.29 μM Compound: 1; Try	Antiproliferative activity against human Bel-7402 cells measured after 48 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells measured after 48 hrs by MTT assay	[PMID: 38665827]
CCRF-CEM	GI₅₀	14.47 μM Compound: Tryptanthrin	Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by eosin exclusion dye based light microscopic method Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by eosin exclusion dye based light microscopic method	[PMID: 32712536]
CCRF-CEM	IC₅₀	44.36 μM Compound: Tryptanthrin	Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by eosin exclusion dye based light microscopic method Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by eosin exclusion dye based light microscopic method	[PMID: 32712536]
DU-145	GI₅₀	0.4 μM Compound: 1 (Tryptanthrine)	Tested for in vitro cytotoxic activity against prostate DU145 human cancer cell lines Tested for in vitro cytotoxic activity against prostate DU145 human cancer cell lines	[PMID: 12161121]
DU-145	GI₅₀	0.4 μM Compound: 1; Try	Growth inhibition of human DU-145 cells assessed as reduction in cell viability Growth inhibition of human DU-145 cells assessed as reduction in cell viability	[PMID: 38665827]
DU-145	GI₅₀	0.4 μM Compound: 47	Growth inhibition of human DU-145 cells by sulforhodamine B assay Growth inhibition of human DU-145 cells by sulforhodamine B assay	[PMID: 36375335]
DU-145	IC₅₀	6.22 μM Compound: 1a	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 22819942]
HCT-116	IC₅₀	17.49 μM Compound: 1; Try	Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay	[PMID: 38665827]
HCT-15	IC₅₀	8.49 μM Compound: 1a	Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 22819942]
HEK293	IC₅₀	0.0537 μM Compound: 5a, Tryptanthrin	Inhibition of human IDO1 expressed in HEK293 cells assessed as kynurenine release after 5 hrs by spectrophotometry Inhibition of human IDO1 expressed in HEK293 cells assessed as kynurenine release after 5 hrs by spectrophotometry	[PMID: 24099220]
HEK293	IC₅₀	0.14 μM Compound: 5a	Inhibition of TDO (unknown origin) expressed in HEK293 cells using L-Trp as substrate after 8 hrs Inhibition of TDO (unknown origin) expressed in HEK293 cells using L-Trp as substrate after 8 hrs	[PMID: 30321802]
HEK293	IC₅₀	4.11 μM Compound: 1a	Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 22819942]
HeLa	IC₅₀	>150 μM Compound: 1; Try	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition Antiproliferative activity against human HeLa cells assessed as cell growth inhibition	[PMID: 38665827]
HepG2	IC₅₀	305.4 ng/mL Compound: tryptanthrin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25654185]
HepG2	IC₅₀	9.51 μM Compound: 1; Try	Antiproliferative activity against human HepG2 cells incubated by 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated by 48 hrs by MTT assay	[PMID: 38665827]
HepG2	IC₅₀	90.14 μM Compound: 1; Try	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth	[PMID: 38665827]
HepG2	IC₅₀	90.14 μM Compound: 1; Try	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 38665827]
HL-60	IC₅₀	2 μM Compound: TBr; 1a	Antiproliferative activity against human HL60 cells after 48 hrs Antiproliferative activity against human HL60 cells after 48 hrs	[PMID: 28720329]
HL-60	IC₅₀	5 μM Compound: TBr; 1a	Antiproliferative activity against human HL60 cells after 24 hrs Antiproliferative activity against human HL60 cells after 24 hrs	[PMID: 28720329]
Huh-7	CC₅₀	>10 μM Compound: GNF-Pf-2691	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
K562	IC₅₀	12.04 μM Compound: 1; Try	Antiproliferative activity against human K562 cells incubated by 48 hrs by MTT assay Antiproliferative activity against human K562 cells incubated by 48 hrs by MTT assay	[PMID: 38665827]
K562	IC₅₀	15 μM Compound: TBr; 1a	Antiproliferative activity against human K562 cells after 24 hrs Antiproliferative activity against human K562 cells after 24 hrs	[PMID: 28720329]
K562	IC₅₀	5 μM Compound: TBr; 1a	Antiproliferative activity against human K562 cells after 48 hrs Antiproliferative activity against human K562 cells after 48 hrs	[PMID: 28720329]
K562	IC₅₀	6.3 μg/mL Compound: 47	Cytotoxicity against human K562 cells assessed reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 36375335]
K562	IC₅₀	8.8 μg/mL Compound: TBr; 1a	Antiproliferative activity against human K562 cells after 48 hrs by MTT staining-based method Antiproliferative activity against human K562 cells after 48 hrs by MTT staining-based method	[PMID: 28720329]
L02	IC₅₀	>100 μM Compound: 1; Try	Antiproliferative activity against human HL7702 cells assessed as inhibition of cell viability Antiproliferative activity against human HL7702 cells assessed as inhibition of cell viability	[PMID: 38665827]
L02	IC₅₀	90.12 μM Compound: 1; Try	Antiproliferative activity against human HL7702 cells assessed as inhibition of cell growth Antiproliferative activity against human HL7702 cells assessed as inhibition of cell growth	[PMID: 38665827]
L02	IC₅₀	90.12 μM Compound: 1; Try	Antiproliferative activity against human HL7702 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HL7702 cells measured after 48 hrs by MTT assay	[PMID: 38665827]
M14	GI₅₀	15 μM Compound: 1 (Tryptanthrine)	Tested for in vitro cytotoxic activity against melanoma M14 human cancer cell lines Tested for in vitro cytotoxic activity against melanoma M14 human cancer cell lines	[PMID: 12161121]
M14	GI₅₀	15 μM Compound: 1; Try	Growth inhibition of human M14 cells assessed as reduction in cell viability Growth inhibition of human M14 cells assessed as reduction in cell viability	[PMID: 38665827]
M14	GI₅₀	15 μM Compound: 47	Growth inhibition of human M14 cells Growth inhibition of human M14 cells	[PMID: 36375335]
MC3T3-E1	IC₅₀	>100 μM Compound: 1; Try	Antiproliferative activity against mouse MC3T3-E1 cells Antiproliferative activity against mouse MC3T3-E1 cells	[PMID: 38665827]
MCF7	IC₅₀	0.58 μM Compound: TBr; 1a	Cytotoxicity against human wild-type MCF7 cells after 72 hrs Cytotoxicity against human wild-type MCF7 cells after 72 hrs	[PMID: 28720329]
MCF7	IC₅₀	11.1 μM Compound: 7	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 18507473]
MCF7	IC₅₀	94.2 μM Compound: 1; Try	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 38665827]
MDA-MB-231	IC₅₀	>100 μM Compound: 1; Try	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	[PMID: 38665827]
MGC-803	IC₅₀	70.19 μM Compound: 1; Try	Antiproliferative activity against human MGC-803 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells measured after 48 hrs by MTT assay	[PMID: 38665827]
MOLT-4	IC₅₀	10 μM Compound: TBr; 1a	Antiproliferative activity against human MOLT4 cells after 24 hrs Antiproliferative activity against human MOLT4 cells after 24 hrs	[PMID: 28720329]
MOLT-4	IC₅₀	8 μM Compound: TBr; 1a	Antiproliferative activity against human MOLT4 cells after 48 hrs Antiproliferative activity against human MOLT4 cells after 48 hrs	[PMID: 28720329]
NCI/ADR-RES	GI₅₀	30 μM Compound: 1 (Tryptanthrine)	Tested for in vitro cytotoxic activity against breast MCF-7/ADR human cancer cell lines Tested for in vitro cytotoxic activity against breast MCF-7/ADR human cancer cell lines	[PMID: 12161121]
NCI/ADR-RES	GI₅₀	30 μM Compound: 1; Try	Growth inhibition of human MCF7ADR cells assessed as reduction in cell viability Growth inhibition of human MCF7ADR cells assessed as reduction in cell viability	[PMID: 38665827]
NCI/ADR-RES	GI₅₀	30 μM Compound: 47	Growth inhibition of human MCF7ADR cells Growth inhibition of human MCF7ADR cells	[PMID: 36375335]
NCI/ADR-RES	IC₅₀	0.03 μM Compound: TBr; 1a	Cytotoxicity against human MCF7/ADR cells after 72 hrs Cytotoxicity against human MCF7/ADR cells after 72 hrs	[PMID: 28720329]
NCI/ADR-RES	IC₅₀	96.4 μM Compound: 1; Try	Antiproliferative activity against human MCF7ADR cells Antiproliferative activity against human MCF7ADR cells	[PMID: 38665827]
NCI-H460	IC₅₀	9 μM Compound: 7	Cytotoxicity against human NCI-H460 cells Cytotoxicity against human NCI-H460 cells	[PMID: 18507473]
NCI-H522	GI₅₀	15 μM Compound: 1 (Tryptanthrine)	Tested for in vitro cytotoxic activity against lung H522 human cancer cell lines Tested for in vitro cytotoxic activity against lung H522 human cancer cell lines	[PMID: 12161121]
NCI-H522	GI₅₀	15 μM Compound: 1; Try	Growth inhibition of human NCI-H522 cells assessed as reduction in cell viability Growth inhibition of human NCI-H522 cells assessed as reduction in cell viability	[PMID: 38665827]
NCI-H522	GI₅₀	15 μM Compound: 47	Growth inhibition of human NCI-H522 cells Growth inhibition of human NCI-H522 cells	[PMID: 36375335]
PC-3	IC₅₀	14.52 μM Compound: 1; Try	Antiproliferative activity against human PC-3 cells incubated by 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells incubated by 48 hrs by MTT assay	[PMID: 38665827]
SF-268	IC₅₀	24.4 μM Compound: 7	Cytotoxicity against human SF268 cells Cytotoxicity against human SF268 cells	[PMID: 18507473]
SH-SY5Y	IC₅₀	22 μM Compound: 47	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability	[PMID: 36375335]
SK-N-DZ	IC₅₀	14 μM Compound: 47	Anticancer activity against human SK-N-DZ cells assessed as cell growth inhibition measured after 72 hrs by DAPI staining based analysis Anticancer activity against human SK-N-DZ cells assessed as cell growth inhibition measured after 72 hrs by DAPI staining based analysis	[PMID: 36375335]
SK-OV-3	GI₅₀	2.5 μM Compound: 1 (Tryptanthrine)	Tested for in vitro cytotoxic activity against ovarian SKOV3 human cancer cell lines Tested for in vitro cytotoxic activity against ovarian SKOV3 human cancer cell lines	[PMID: 12161121]
SK-OV-3	GI₅₀	2.5 μM Compound: 1; Try	Growth inhibition of human SK-OV-3 cells assessed as reduction in cell viability Growth inhibition of human SK-OV-3 cells assessed as reduction in cell viability	[PMID: 38665827]
SK-OV-3	GI₅₀	2.5 μM Compound: 47	Growth inhibition of human SK-OV-3 cells by sulforhodamine B assay Growth inhibition of human SK-OV-3 cells by sulforhodamine B assay	[PMID: 36375335]
SK-OV-3	IC₅₀	85.09 μM Compound: 1; Try	Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth	[PMID: 38665827]
SW-620	GI₅₀	5 μM Compound: 1 (Tryptanthrine)	Tested for in vitro cytotoxic activity against colon SW620 human cancer cell lines Tested for in vitro cytotoxic activity against colon SW620 human cancer cell lines	[PMID: 12161121]
SW-620	GI₅₀	5 μM Compound: 1; Try	Growth inhibition of human SW620 cells assessed as reduction in cell viability Growth inhibition of human SW620 cells assessed as reduction in cell viability	[PMID: 38665827]
SW-620	GI₅₀	5 μM Compound: 47	Growth inhibition of human SW620 cells Growth inhibition of human SW620 cells	[PMID: 36375335]
T-24	IC₅₀	>150 μM Compound: 1; Try	Antiproliferative activity against human T24 cells assessed as inhibition of cell growth Antiproliferative activity against human T24 cells assessed as inhibition of cell growth	[PMID: 38665827]
T-24	IC₅₀	>150 μM Compound: 1; Try	Antiproliferative activity against human T24 cells measured after 48 hrs by MTT assay Antiproliferative activity against human T24 cells measured after 48 hrs by MTT assay	[PMID: 38665827]
T47D	IC₅₀	14.29 μM Compound: 1a	Cytotoxicity against human T47D cells after 72 hrs by MTT assay Cytotoxicity against human T47D cells after 72 hrs by MTT assay	[PMID: 22819942]
U-251	GI₅₀	100 μM Compound: 1 (Tryptanthrine)	Tested for in vitro cytotoxic activity against CNS U251 human cancer cell lines Tested for in vitro cytotoxic activity against CNS U251 human cancer cell lines	[PMID: 12161121]
U-251	GI₅₀	100 μM Compound: 1; Try	Growth inhibition of human U-251 cells assessed as reduction in cell viability Growth inhibition of human U-251 cells assessed as reduction in cell viability	[PMID: 38665827]
U-251	GI₅₀	100 μM Compound: 47	Growth inhibition of human U-251 cells Growth inhibition of human U-251 cells	[PMID: 36375335]
U-87MG ATCC	IC₅₀	0.194 μM Compound: 5a	Inhibition of TDO in human U87 MG cells using L-Trp as substrate after 8 hrs Inhibition of TDO in human U87 MG cells using L-Trp as substrate after 8 hrs	[PMID: 30321802]
U-87MG ATCC	IC₅₀	5 μM Compound: 5a	Inhibition of recombinant human IDO2 expressed in human U87MG cells assessed as reduction in kynurenine formation using L-tryptophan as substrate after 6 hrs by spectrophotometry Inhibition of recombinant human IDO2 expressed in human U87MG cells assessed as reduction in kynurenine formation using L-tryptophan as substrate after 6 hrs by spectrophotometry	[PMID: 27475108]
U-937	IC₅₀	3.1 μg/mL Compound: 47	Cytotoxicity against human U-937 cells assessed reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human U-937 cells assessed reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 36375335]
Vero	IC₅₀	>100 μg/mL Compound: 2	Cytotoxicity against African green monkey Vero cells by CellTiter 96 aqueous nonradioactive cell proliferation assay Cytotoxicity against African green monkey Vero cells by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 30295480]
Vero	IC₅₀	>8 μg/mL Compound: 1a, Tryptanthrin	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 23360475]
WEHI3B	IC₅₀	1.5 μM Compound: 1; Try	Antiproliferative activity against mouse WEHI3B cells assessed as inhibition of cell growth measured after 48 hrs Antiproliferative activity against mouse WEHI3B cells assessed as inhibition of cell growth measured after 48 hrs	[PMID: 38665827]

In Vitro

Tryptanthrin (0-60 μM; 24, 48 and 72 h) inhibits the proliferation and colony formation of MCF-7 cells^[1].
Tryptanthrin (6.25-25 μM; 48 h; MCF-7 cells) reverses EMT-associated E-cadherin, MMP-2 and Snail^[1].
Tryptanthrin (0-30 μM; 15 min; MCF-7 cells) reduces Leukotriene (LT)-formation in human neutrophils with an IC₅₀ value of 0.6 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

MCF-7 cells
Concentration:

0-60 μM
Incubation Time:

24, 48 and 72 hours
Result:

Increased the inhibition rates of MCF-7 cells in a dose- and time- dependent manner.

Western Blot Analysis^[1]

Cell Line:

MCF-7 cells
Concentration:

6.25, 12.5, and 25 μM
Incubation Time:

48 hours
Result:

Increased the E-cadherin protein levels and markedly upregulated the protein expression levels of MMP-2 and Snail in MCF-7 cells induced by TGF-β1.

In Vivo

Tryptanthrin (25-100 mg/kg; i.g.; daily, for 13 d; Female Bal b/c mice with 4T1 xenograft) inhibits tumor growth and regulates IL-2, IL-6, IL-10, IL-12 and TNF-α levels in tumor-bearing mice^[1].
Tryptanthrin (10 mg/kg; p.o.; male Wistar Han rats) inhibits LTB₄ formation in vivo^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female Bal b/c mice with 4T1 xenograft^[1]
Dosage:

25, 50, and 100 mg/kg
Administration:

Oral gavage; daily, for 13 days
Result:

Inhibited tumor growth in a dose-dependent manner.

Animal Model:

Male Wistar Han rats (220–230 g)^[2]
Dosage:

10 mg/kg
Administration:

Oral administration; once
Result:

Reduced LTB₄ pleural levels by 46%.
Reduced PGE₂ levels (by 42%), exudate volume (by 80%) and the number of infiltrating cells (by 41%).

Chemical Information

CAS. Nr. 13220-57-0
Appearance Solid
Molecular Weight 248.24
Formel C₁₅H₈N₂O₂
Color Light yellow to yellow
SMILES

O=C1C2=CC=CC=C2N3C(C4=CC=CC=C4N=C13)=O
Structure Classification
- Alkaloids
- Indole Alkaloids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All IFRT-PCRWBHistological Imaging/StainingIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Phytomedicine

Tryptanthrin suppresses multiple inflammasome activation to regulate NASH progression by targeting ASC protein. [Abstract]

2024 Aug:131:155758. PMID: 38843643
Neural Regen Res

Pharmacological targeting cGAS/STING/NF-κB axis by tryptanthrin induces microglia polarization toward M2 phenotype and promotes functional recovery in a mouse model of spinal cord injury. [Abstract]

2025 Nov 1;20(11):3287-3301. PMID: 38993129

Tryptanthrin purchased from MedChemExpress. Usage Cited in: Neural Regen Res. 2025 Nov 1;20(11):3287-3301. [Abstract]

Double immunostaining of phallotoxin (purple) and Iba1 (green) of BV2 cells incubated with different levels of Tryptanthrin (Tryp) (0, 2.5, 5.0, and 10.0 μM) with or without LPS for 24 hours.

Tryptanthrin purchased from MedChemExpress. Usage Cited in: Neural Regen Res. 2025 Nov 1;20(11):3287-3301. [Abstract]

Quantitative reverse transcription-polymerase chain reaction analysis of IL-6, IL1β, TNF-α , CD206 and Arg-1 gene expression levels in BV2 cells incubated with different levels of Tryptanthrin (Tryp) (0, 2.5, 5.0, 10.0 μM) with or without LPS for 24 hours.

Tryptanthrin purchased from MedChemExpress. Usage Cited in: Neural Regen Res. 2025 Nov 1;20(11):3287-3301. [Abstract]

Western blot analysis of CD206 and CD86 in BV2 cells incubated with various concentrations of Tryptanthrin (Tryp) (0, 2.5, 5.0, 10.0 μM) with or without LPS for 24 hours.

Tryptanthrin purchased from MedChemExpress. Usage Cited in: Neural Regen Res. 2025 Nov 1;20(11):3287-3301. [Abstract]

Typical hematoxylin-eosin staining images showing the lesion area (labeled by black dashed lines) in spinal cords at 7 and 14 dpi treated with Tryptanthrin (Tryp) (30 mg/kg/day, i.g.).

Tryptanthrin purchased from MedChemExpress. Usage Cited in: Neural Regen Res. 2025 Nov 1;20(11):3287-3301. [Abstract]

Quantitative analysis of motor function measured via BMS scoring analysis at different stages in mice treated with Tryptanthrin (Tryp) (30 mg/kg/day, i.g.) after SCI.
Biochem Pharmacol

Pharmacokinetics of major indigo naturalis indole alkaloids in humans and their association with systemic aryl hydrocarbon receptor activity. [Abstract]

2025 Feb 22:116805. PMID: 39993611
Int Immunopharmacol

Tryptanthrin promotes pressure ulcers healing in mice by inhibiting macrophage-mediated inflammation via cGAS/STING pathways. [Abstract]

2024 Mar 30:130:111687. PMID: 38382260
ACS Omega

Identification of Phialomustin‑B (PHL-B) as a Novel Natural TRPA1 Channel Inhibitor. [Abstract]

2025 Aug 21;10(34):39192-39202. PMID: 40918390
ACS Omega

Exploring the Anti-Inflammatory Effect of Tryptanthrin by Regulating TLR4/MyD88/ROS/NF-κB, JAK/STAT3, and Keap1/Nrf2 Signaling Pathways. [Abstract]

2024 Jul 3;9(28):30904-30918. PMID: 39035974
PLoS Pathog

G-quadruplex in the TMV Genome Regulates Viral Proliferation and Acts as Antiviral Target of Photodynamic Therapy. [Abstract]

2023 Dec 7;19(12):e1011796. PMID: 38060599
iScience

Acinetobacter baumannii biofilm was inhibited by tryptanthrin through disrupting its different stages and genes expression. [Abstract]

2024 May 8;27(6):109942. PMID: 38812547

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 7.14 mg/mL (28.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.0284 mL

20.1418 mL

40.2836 mL

5 mM

0.8057 mL

4.0284 mL

8.0567 mL

10 mM

0.4028 mL

2.0142 mL

4.0284 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 0.71 mg/mL (2.86 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 0.71 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.1 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 0.67 mg/mL (2.70 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 0.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zeng Q, et, al. Tryptanthrin exerts anti-breast cancer effects both in vitro and in vivo through modulating the inflammatory tumor microenvironment. Acta Pharm. 2021 Jun 1;71(2):245-266. [Content Brief]

[2]. Pergola C, et, al. On the inhibition of 5-lipoxygenase product formation by tryptanthrin: mechanistic studies and efficacy in vivo. Br J Pharmacol. 2012 Feb;165(3):765-76. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.0284 mL	20.1418 mL	40.2836 mL	100.7090 mL
	5 mM	0.8057 mL	4.0284 mL	8.0567 mL	20.1418 mL
	10 mM	0.4028 mL	2.0142 mL	4.0284 mL	10.0709 mL
	15 mM	0.2686 mL	1.3428 mL	2.6856 mL	6.7139 mL
	20 mM	0.2014 mL	1.0071 mL	2.0142 mL	5.0354 mL
	25 mM	0.1611 mL	0.8057 mL	1.6113 mL	4.0284 mL

Keywords

Tryptanthrin

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Tryptanthrin

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) Tryptanthrin

Alle Leukotriene Receptor Isoform-spezifische Produkte anzeigen

Alle NO Synthase Isoform-spezifische Produkte anzeigen

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle COX Isoform-spezifische Produkte anzeigen

Alle TNF Receptor Isoform-spezifische Produkte anzeigen

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table